bioAffinity Technologies reported a net loss of approximately $5.3 million for the third quarter ended September 30, 2026, compared to a $5.1 million loss in the prior-year period. Total revenue declined to roughly $1.1 million from $1.4 million, driven by lower reimbursement rates and fewer test cases at its laboratory partner. However, year-to-date testing revenue rose 79% to approximately $1.1 million, and unit sales doubled compared to the first nine months of 2025. The company raised an aggregate of $8.0 million in gross proceeds through private placements in August and October 2026 for working capital. bioAffinity Technologies develops noninvasive diagnostic tests for lung disease and topically delivered therapeutics for skin cancer.
